Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Berenberg Bank Stick to Their Buy Rating for Ascendis Pharma

Published 08/29/2021, 07:25 AM
Updated 08/29/2021, 07:25 AM


Berenberg Bank analyst Anita Dushyanth maintained a Buy rating on Ascendis Pharma (NASDAQ:ASND) on Friday, setting a price target of $213, which is approximately 37.63% above the present share price of $154.76.

Dushyanth expects Ascendis Pharma to post earnings per share (EPS) of -$2.50 for the third quarter of 2021.

The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Ascendis Pharma, with an average price target of $194.78.
The analysts price targets range from a high of $213 to a low of $175.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.02 million and a net profit of -$117.63 million. The company's market cap is $8.34 billion.

According to TipRanks.com, Berenberg Bank analyst Anita Dushyanth is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.0% and a 18.18% success rate.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.